Skip to main content
Premium Trial:

Request an Annual Quote

Migrations: Jan 30, 2009


The Massachusetts Life Sciences Center this week announced the addition of Jonathan Fleming, Doug Cole, and Jean George to the organization’s scientific advisory board, bringing the board’s total membership to fifteen.

Fleming is the managing general partner of Oxford Bioscience Partners. Prior to joining OBP in 1996, he was a founding general partner of MVP Ventures. He began his investment career with TVM Techno Venture Management. Fleming also co-founded Medica Venture Partners.

Cole is currently a general partner at Flagship Ventures. While at Flagship, Cole co-founded Ensemble Discovery with Noubar Afeyan and David Liu of Harvard University, and he served as chief executive officer of the company its initial stages.

He was previously medical director of Cytotherapeutics. Cole was then appointed program executive at Vertex Pharmaceuticals.

Jean George is a partner at Advanced Technology Ventures. Prior to joining ATV, George was a director at BancBoston Ventures. Previously, George held a variety of roles in marketing, product development, and business development at Genzyme, including vice president of global sales and marketing.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.